IL235927A - A drug that contains vascular disruption and causes oxygen deficiency to treat cancer - Google Patents
A drug that contains vascular disruption and causes oxygen deficiency to treat cancerInfo
- Publication number
- IL235927A IL235927A IL235927A IL23592714A IL235927A IL 235927 A IL235927 A IL 235927A IL 235927 A IL235927 A IL 235927A IL 23592714 A IL23592714 A IL 23592714A IL 235927 A IL235927 A IL 235927A
- Authority
- IL
- Israel
- Prior art keywords
- agent
- composition
- cancer treatment
- vascular disrupting
- targets hypoxia
- Prior art date
Links
- 206010021143 Hypoxia Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 230000007954 hypoxia Effects 0.000 title 1
- 239000004066 vascular targeting agent Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012902291A AU2012902291A0 (en) | 2012-06-01 | Combination Therapy | |
| PCT/AU2013/000581 WO2013177633A1 (en) | 2012-06-01 | 2013-06-03 | Combination therapy involving a vascular disrupting agent and an agent which targets hypoxia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL235927A0 IL235927A0 (en) | 2015-01-29 |
| IL235927A true IL235927A (en) | 2017-11-30 |
Family
ID=49672192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL235927A IL235927A (en) | 2012-06-01 | 2014-11-26 | A drug that contains vascular disruption and causes oxygen deficiency to treat cancer |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20150133401A1 (https=) |
| EP (1) | EP2854796B1 (https=) |
| JP (1) | JP6005855B2 (https=) |
| CN (1) | CN104703595B (https=) |
| AU (2) | AU2013204313C1 (https=) |
| CA (1) | CA2874778A1 (https=) |
| IL (1) | IL235927A (https=) |
| NZ (1) | NZ630465A (https=) |
| WO (1) | WO2013177633A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016228116A1 (en) * | 2015-03-05 | 2017-09-14 | Bionomics Limited | Combination treatment protocol |
| SG11201707128TA (en) * | 2015-03-06 | 2017-09-28 | Beyondspring Pharmaceuticals Inc | Method of treating a brain tumor |
| AU2016229294B2 (en) | 2015-03-06 | 2021-11-04 | Beyondspring Pharmaceuticals, Inc. | Method of treating cancer associated with a RAS mutation |
| JP6969848B2 (ja) | 2015-07-13 | 2021-11-24 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | プリナブリン組成物 |
| KR20180105685A (ko) | 2016-02-08 | 2018-09-28 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 투카레솔 또는 이의 유사체를 함유하는 조성물 |
| JP7025416B2 (ja) | 2016-06-06 | 2022-02-24 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 好中球減少症を低減させるための組成物および方法 |
| WO2018129381A1 (en) | 2017-01-06 | 2018-07-12 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| BR112019015974A2 (pt) | 2017-02-01 | 2020-03-31 | Beyondspring Pharmaceuticals, Inc. | Método para reduzir neutropenia |
| JP2020534289A (ja) * | 2017-09-14 | 2020-11-26 | ランケナー インスティテュート フォー メディカル リサーチ | がんの治療のための方法および組成物 |
| KR20200112881A (ko) | 2018-01-24 | 2020-10-05 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법 |
| CN110680824A (zh) * | 2018-07-05 | 2020-01-14 | 深圳艾欣达伟医药科技有限公司 | 埃夫索胺的抗癌医药用途 |
| CN109675039A (zh) * | 2018-12-21 | 2019-04-26 | 中国科学院长春应用化学研究所 | 药物组合、抗肿瘤的药物和应用 |
| CN112755188B (zh) * | 2019-11-01 | 2022-03-08 | 中国科学院微生物研究所 | Shmt2抑制剂在制备抑制膀胱癌细胞生长和转移的药物中的应用 |
| CA3215047A1 (en) | 2021-04-09 | 2022-10-13 | Lan Huang | Therapeutic compositions and methods for treating tumors |
| WO2023025312A1 (zh) | 2021-08-27 | 2023-03-02 | 深圳艾欣达伟医药科技有限公司 | 使用th-302治疗parp抑制剂耐药的患者 |
| CN117651548B (zh) | 2021-08-27 | 2026-03-03 | 深圳艾欣达伟医药科技有限公司 | 冻干制剂溶液及冻干制剂、方法和用途 |
| US20250186468A1 (en) | 2022-03-15 | 2025-06-12 | Ascentawits Pharmaceuticals, Ltd. | Method for treating patient with brca-mutated cancer |
| CN119384281A (zh) | 2022-04-15 | 2025-01-28 | 深圳艾欣达伟医药科技有限公司 | 使用th-302单药或联用parp抑制剂治疗癌症的方法 |
| CN119233822A (zh) | 2022-05-23 | 2024-12-31 | 深圳艾欣达伟医药科技有限公司 | 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法 |
| CN119894521A (zh) | 2022-09-22 | 2025-04-25 | 深圳艾欣达伟医药科技有限公司 | 乏氧激活的化合物在制备治疗癌症患者的药物中的用途 |
| KR20250160163A (ko) | 2023-02-27 | 2025-11-11 | 아센타위츠 파마슈티컬즈 리미티드 | 용액, 동결건조 제형, 동결건조 제형 단위 패키지, 주사제, 및 주사제 제조 방법 |
| WO2025026214A1 (zh) | 2023-07-28 | 2025-02-06 | 深圳艾欣达伟医药科技有限公司 | 治疗p53基因突变或缺陷阴性癌症、肿瘤患者 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5340062A (en) | 1992-08-13 | 1994-08-23 | Harmon Industries, Inc. | Train control system integrating dynamic and fixed data |
| US5886025A (en) | 1997-03-06 | 1999-03-23 | Baylor University | Anti-mitotic agents which inhibit tubulin polymerization |
| US6162930A (en) | 1998-03-06 | 2000-12-19 | Baylor University | Anti-mitotic agents which inhibit tubulin polymerization |
| US6849656B1 (en) | 1999-09-17 | 2005-02-01 | Baylor University | Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents |
| AUPR283801A0 (en) | 2001-02-01 | 2001-03-01 | Australian National University, The | Chemical compounds and methods |
| WO2003070241A1 (en) | 2002-02-15 | 2003-08-28 | Rigel Pharmaceuticals, Inc. | Inhibitors of tubulin polymerization |
| US7456214B2 (en) | 2004-05-03 | 2008-11-25 | Baylor University | Chromene-containing compounds with anti-tubulin and vascular targeting activity |
| AU2006212726C1 (en) | 2005-02-14 | 2013-05-16 | Bionomics Limited | Novel tubulin polymerisation inhibitors |
| ES2551086T3 (es) | 2005-06-14 | 2015-11-16 | Baylor University | Análogos de combretastatina con actividad de unión a tubulina |
| JP5315060B2 (ja) * | 2006-02-03 | 2013-10-16 | バイオノミックス リミテッド | 置換ベンゾフラン、ベンゾチオフェン、ベンゾセレノフェンおよびインドールおよびそれらのチューブリン重合阻害剤としての使用 |
| US8466163B2 (en) | 2006-12-11 | 2013-06-18 | Bionomics Limited | Furo[2,3-d]pyrimidines and related compounds and methods for treating disease states by inhibiting tubulin polymerization |
| CN104043125B (zh) * | 2008-04-10 | 2018-01-12 | 弗吉尼亚州立邦联大学 | 诱导肿瘤缺氧以治疗癌症 |
| US20110130367A1 (en) * | 2009-11-27 | 2011-06-02 | Bionomics Limited | Combination Therapy for Treating Proliferative Diseases |
| WO2011063469A1 (en) * | 2009-11-27 | 2011-06-03 | Bionomics Limited | Tubulin biomarker assay |
| CA2686587C (en) * | 2009-11-27 | 2018-01-16 | Bionomics Limited | Combination therapy for treating proliferative diseases |
| ES2877629T3 (es) * | 2010-07-12 | 2021-11-17 | Immunogenesis Inc | Administración de profármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer |
-
2013
- 2013-04-12 AU AU2013204313A patent/AU2013204313C1/en not_active Ceased
- 2013-06-03 AU AU2013270425A patent/AU2013270425A1/en not_active Abandoned
- 2013-06-03 CA CA2874778A patent/CA2874778A1/en not_active Abandoned
- 2013-06-03 US US14/404,782 patent/US20150133401A1/en not_active Abandoned
- 2013-06-03 CN CN201380035499.3A patent/CN104703595B/zh not_active Expired - Fee Related
- 2013-06-03 NZ NZ630465A patent/NZ630465A/en not_active IP Right Cessation
- 2013-06-03 WO PCT/AU2013/000581 patent/WO2013177633A1/en not_active Ceased
- 2013-06-03 JP JP2015514291A patent/JP6005855B2/ja not_active Expired - Fee Related
- 2013-06-03 EP EP13797528.0A patent/EP2854796B1/en not_active Not-in-force
-
2014
- 2014-11-26 IL IL235927A patent/IL235927A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015518008A (ja) | 2015-06-25 |
| CA2874778A1 (en) | 2013-12-05 |
| IL235927A0 (en) | 2015-01-29 |
| AU2013204313B2 (en) | 2015-09-03 |
| CN104703595A (zh) | 2015-06-10 |
| HK1207286A1 (en) | 2016-01-29 |
| WO2013177633A1 (en) | 2013-12-05 |
| AU2013204313C1 (en) | 2016-04-07 |
| EP2854796B1 (en) | 2018-11-14 |
| US20150133401A1 (en) | 2015-05-14 |
| NZ630465A (en) | 2015-09-25 |
| EP2854796A4 (en) | 2015-10-14 |
| JP6005855B2 (ja) | 2016-10-12 |
| CN104703595B (zh) | 2017-07-28 |
| EP2854796A1 (en) | 2015-04-08 |
| AU2013204313A1 (en) | 2013-12-19 |
| AU2013270425A1 (en) | 2014-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL235927A (en) | A drug that contains vascular disruption and causes oxygen deficiency to treat cancer | |
| IL267242B (en) | Cancer treatment | |
| PL2740793T3 (pl) | Kompozycja leku do leczenia i/lub zapobiegania nowotworowi | |
| PL2818483T3 (pl) | Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi | |
| PL2740795T3 (pl) | Kompozycja lekowa do leczenia nowotworu i/lub zapobiegania nowotworowi | |
| PL2740798T3 (pl) | Kompozycja leku do leczenia i/lub zapobiegania nowotworom | |
| PL2925888T3 (pl) | Kompozycje i sposoby do stosowania w leczeniu nowotworów | |
| HUE044611T2 (hu) | Gyógyászati készítmény rák kezelésére | |
| PL2824114T3 (pl) | Kompozycja farmaceutyczna do leczenia nowotworu | |
| PL2818481T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi złośliwemu | |
| PT3821830T (pt) | Dispositivo para tratar a oclusão vascular | |
| PL2532366T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi | |
| ZA201300692B (en) | Administration of hypoxia activated prodrugs and antiagiogenic agents for the treatment of cancer | |
| PL3967315T3 (pl) | Akkermansia muciniphila do leczenia nowotworu złośliwego | |
| HUE036424T2 (hu) | Gyógyászati készítmény májrák kezelésére és/vagy megelõzésére | |
| EP2825239A4 (en) | CATHETER HAVING ANTIMICROBIAL COATING | |
| IL238177A0 (en) | Methods and preparations for the treatment of cancer | |
| SG11201400976WA (en) | Methods and pharmaceutical compositions for treating cancer | |
| EP3020399A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF CANCER | |
| DK2872176T3 (en) | Cancer treatment | |
| EP2934500A4 (en) | COMBINATION THERAPY AGAINST CANCER | |
| PL2855475T3 (pl) | Alfa-karboliny do leczenia nowotworu | |
| SG11201509433RA (en) | Composition comprising a complex of (+)-catechin and amino acid for the treatment and prevention of cancer | |
| PL2663318T3 (pl) | Kompozycja farmaceutyczna do leczenia raka | |
| EP2887967A4 (en) | COMPOSITIONS AND METHODS FOR TREATING HEPATOCELLULAR CANCER |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |